| Autor: |
Szekely J; Faculty of Medical Technology, Prince of Songkla University, Hat Yai 90110, Thailand., Swangphon P; Faculty of Medical Technology, Prince of Songkla University, Hat Yai 90110, Thailand., Nanakorn N; Faculty of Medical Technology, Prince of Songkla University, Hat Yai 90110, Thailand., Chaimuti P; Immunology and Virology Unit, Department of Medical Technology and Clinical Pathology, Hat Yai Hospital, Hat Yai 90110, Thailand., Nualnoi T; Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai 90110, Thailand., Wongwitwichot P; Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai 90110, Thailand., Somapa N; Master Labs Incorporation Co., Ltd., Bangkok 10510, Thailand., Somapa D; Master Labs Incorporation Co., Ltd., Bangkok 10510, Thailand., Pengsakul T; Faculty of Environmental Management, Prince of Songkla University, Hat Yai 90110, Thailand.; Health and Environmental Research Center, Faculty of Environmental Management, Prince of Songkla University, Hat Yai 90110, Thailand. |
| Abstrakt: |
This study aims to analyze the neutralization ability against Omicron parental variants in five clusters of individuals with different Coronavirus disease (COVID-19) immunity backgrounds, including individuals receiving a homologous or heterologous vaccine without prior infection, recovered patients with homologous or heterologous vaccination, and recovery patients without vaccination. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) surrogate virus neutralization assay was performed on serum samples. Spearman correlation analysis showed that the percent inhibition against Omicron B.1.1.529 and BA.2 was significantly related to the period of serum collection ( r = 0.730 and 0.787, p < 0.001, respectively). Very strong correlation between percent inhibition of neutralizing antibody against Omicron B.1.1.529 and BA.2 variants ( r s = 0.973, p < 0.001) was also observed. The neutralizing activity of the sera from recovery patients receiving homologous and heterologous vaccine against the wild-type, B.1.1.529, and BA.2 Omicron variants was significantly higher ( p < 0.001) than that of recovery patients without vaccination. This study robustly showed that the breakthrough SARS-CoV-2 Omicron variant in individuals who received homologous and heterologous vaccines had a high level of neutralizing activity against B.1.1.529 and BA.2 parental lineage of XBB subvariants. Therefore, the next-generation COVID-19 vaccine against emerging variants is needed to improve resilience against ongoing variants, particularly for persons who have never been infected. |
